Quantinno Capital Management LP Purchases 236,256 Shares of Edwards Lifesciences Corporation $EW

Quantinno Capital Management LP increased its position in Edwards Lifesciences Corporation (NYSE:EW) by 58.6% in the first quarter, Holdings Channel.com reports. The firm owned 639,603 shares of the medical research company’s stock after acquiring an additional 236,256 shares during the period. Quantinno Capital Management LP’s holdings in Edwards Lifesciences were worth $51,219,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in EW. Norges Bank acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after buying an additional 4,108,270 shares during the period. Viking Global Investors LP bought a new position in Edwards Lifesciences in the third quarter valued at approximately $238,688,000. Marshall Wace LLP grew its holdings in Edwards Lifesciences by 66.1% during the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after acquiring an additional 2,359,128 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its holdings in Edwards Lifesciences by 341.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,890,859 shares of the medical research company’s stock worth $151,420,000 after acquiring an additional 1,462,238 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares in the company, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 45,577 shares of company stock worth $3,855,527 in the last ninety days. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $85.78 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The firm has a market cap of $49.39 billion, a price-to-earnings ratio of 49.30, a price-to-earnings-growth ratio of 2.10 and a beta of 0.86. The stock’s 50-day moving average is $87.83 and its 200-day moving average is $83.86. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the previous year, the firm posted $0.67 earnings per share. The firm’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Truist Financial raised their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a report on Thursday, July 16th. Mizuho boosted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Finally, JPMorgan Chase & Co. upped their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.